EA201591856A1 - Лечение сердечной недостаточности - Google Patents

Лечение сердечной недостаточности

Info

Publication number
EA201591856A1
EA201591856A1 EA201591856A EA201591856A EA201591856A1 EA 201591856 A1 EA201591856 A1 EA 201591856A1 EA 201591856 A EA201591856 A EA 201591856A EA 201591856 A EA201591856 A EA 201591856A EA 201591856 A1 EA201591856 A1 EA 201591856A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heart failure
treatment
p1gf
mammals
prevention
Prior art date
Application number
EA201591856A
Other languages
English (en)
Other versions
EA032864B1 (ru
Inventor
Штефан Янссенс
Мин Ву
Original Assignee
Кобиорес Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кобиорес Нв filed Critical Кобиорес Нв
Publication of EA201591856A1 publication Critical patent/EA201591856A1/ru
Publication of EA032864B1 publication Critical patent/EA032864B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к лечению и/или предотвращению сердечной недостаточности или одного или более индивидуальных фенотипов сердечной недостаточности у млекопитающих с применением плацентарного фактора роста 2 (P1GF-2).
EA201591856A 2013-05-31 2014-05-30 ПРИМЕНЕНИЕ БЕЛКА PlGF-2 ДЛЯ ЛЕЧЕНИЯ И ПРЕДОТВРАЩЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ EA032864B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829393P 2013-05-31 2013-05-31
EP13176638 2013-07-16
PCT/EP2014/061259 WO2014191553A2 (en) 2013-05-31 2014-05-30 Heart failure treatment

Publications (2)

Publication Number Publication Date
EA201591856A1 true EA201591856A1 (ru) 2016-05-31
EA032864B1 EA032864B1 (ru) 2019-07-31

Family

ID=48783128

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591856A EA032864B1 (ru) 2013-05-31 2014-05-30 ПРИМЕНЕНИЕ БЕЛКА PlGF-2 ДЛЯ ЛЕЧЕНИЯ И ПРЕДОТВРАЩЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

Country Status (10)

Country Link
US (2) US20160082084A1 (ru)
EP (2) EP3511014A1 (ru)
JP (1) JP6458009B2 (ru)
KR (1) KR20160016796A (ru)
CN (1) CN105451758A (ru)
AU (1) AU2014273027B2 (ru)
CA (1) CA2913676A1 (ru)
EA (1) EA032864B1 (ru)
HK (1) HK1223280A1 (ru)
WO (1) WO2014191553A2 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085755A1 (en) * 2016-11-04 2018-05-11 The Johns Hopkins University Risk stratification for ventricular arrhythmia in patients with repaired tetralogy of fallot (tof) via image-based computational simulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229454T2 (de) * 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
ITRM20020277A1 (it) 2002-05-17 2003-11-17 Geymonat Spa Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
AU2006244639A1 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
US20080300797A1 (en) * 2006-12-22 2008-12-04 Aviir, Inc. Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP2090891A1 (en) * 2008-02-13 2009-08-19 F.Hoffmann-La Roche Ag Means and methods for determining the atherosclerotic load using the biomarker PLGF
CA2741117A1 (en) * 2008-10-30 2010-05-06 Centre De Recherche Public De La Sante Biomarkers for heart failure
WO2014117155A1 (en) * 2013-01-28 2014-07-31 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy

Also Published As

Publication number Publication date
EA032864B1 (ru) 2019-07-31
WO2014191553A2 (en) 2014-12-04
WO2014191553A3 (en) 2015-01-29
US20170319656A1 (en) 2017-11-09
CA2913676A1 (en) 2014-12-04
EP3003354B1 (en) 2019-02-06
US20160082084A1 (en) 2016-03-24
EP3003354A2 (en) 2016-04-13
AU2014273027A1 (en) 2015-12-10
JP6458009B2 (ja) 2019-01-23
EP3511014A1 (en) 2019-07-17
CN105451758A (zh) 2016-03-30
AU2014273027B2 (en) 2019-07-04
JP2016520607A (ja) 2016-07-14
KR20160016796A (ko) 2016-02-15
HK1223280A1 (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
EA201890204A1 (ru) Антибактериальные соединения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
NZ730865A (en) Peptides having anti-inflammatory properties
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
EA201990043A1 (ru) Антибактериальные соединения
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
DK3476395T3 (da) Injicerbar sammensætning omfattende fibroblaster til anvendelse i behandlingen af hjertesygdomme
EA202090108A1 (ru) Применение церебролизина
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EA201591856A1 (ru) Лечение сердечной недостаточности
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU